Free shipping on all orders over $ 500

Bemarituzumab

Cat. No. M21498
Bemarituzumab Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).

Chemical Information
CAS Number 1952272-74-0
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Peter Sidaway. Nat Rev Clin Oncol. Bemarituzumab enters the FIGHT

[2] Zev A Wainberg, et al. Lancet Oncol. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

[3] Hong Xiang, et al. MAbs. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

[4] No authors listed. Cancer Discov. Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma

[5] Daniel Vt Catenacci, et al. Future Oncol. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design

Related FGFR Products
LY-3076226

LY-3076226 is an antibody drug coupling (ADC) with a cleavable linker targeting FGFR2.

Aprutumab ixadotin

Aprutumab ixadotin is an antibody drug coupling (ADC) with a non-cleavable linker that targets FGFR2.

Gunagratinib

Gunagratinib is an orally active, potent, selective, and irreversible fibroblast growth factor receptor (pan-FGFR) inhibitor for use in cancer research.

SAR-442501

SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH).

TYRA-200

TYRA-200 is an FGFR1/2/3 (FGFR2 mutation) inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Bemarituzumab supplier, FGFR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.